That unexplained morning bloating or stomach discomfort might have less to do with what you ate and more with how you slept.

An immuno-based treatment targeting cancer cells with mismatch repair-deficiency could help those with the disease treat ...

Please provide your email address to receive an email when new articles are posted on . Biomarker testing appeared inconsistent, with rates not reflecting guidelines. Less than 25% of oncologists ...

A modified FLOT regimen (fluorouracil, oxaliplatin, and docetaxel; TFOX) outperformed a standard chemotherapy triplet for the ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding surgery and harsh treatments.

Dostarlimab offers hope in cancer treatment. Study shows tumour shrinkage in patients with mismatch repair defect. Some ...

A "groundbreaking" cancer treatment trial by Memorial Sloan Kettering shows immunotherapy alone can eliminate some tumors, ...

esophageal cancer, head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), and cervical cancer patients for treatment with KEYTRUDA. Consequently, PD-L1 IHC 22C3 ...

European certification for PD-L1 IHC 22C3 pharmDx to help gastric or GEJ adenocarcinoma patients for KEYTRUDA® therapy SANTA ...

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning they did not need to undergo surgery, radiation or chemotherapy.

A majority (56-57%) had cancers of the gastroesophageal junction, with stomach cancers in the remaining. Nearly all (98-99%) had metastatic disease, with two or more sites of involvement in about ...